Prostate Cancer

Researchers are developing a prognostic hypoxia gene signature for patients with localized prostate cancer that could predict biochemical failure and metastasis.

The US Food and Drug Administration has approved abiraterone acetate (Zytiga) tablets in combination with prednisone for the treatment of metastatic prostate cancer patients with high-risk, castration-sensitive disease.

Adding docetaxel chemotherapy to frontline hormone therapy improves quality of life and may reduce the need for subsequent treatment, according to an analysis from the STAMPEDE trial.

Apalutamide was well-tolerated and associated with delayed metastasis in men with high-risk castration-resistant prostate cancer that has become refractory to conventional hormone therapy, according to an early interim analysis of the phase III SPARTAN clinical trial.

Adjuvant radiotherapy after prostatectomy resulted in lower rates of biochemical recurrence, distant metastases, and death compared with surveillance followed by early-salvage radiotherapy in patients with high-risk prostate cancer, according to a new study.

Long-term follow-up of a large phase III study showed that chemohormonal therapy involving docetaxel added to androgen deprivation therapy (ADT) prolongs overall survival over ADT alone in metastatic hormone-sensitive prostate cancer patients with high-volume disease.

The time to testosterone rebound was associated with differences in prostate cancer–specific and cardiovascular mortality among men who underwent RT and ADT.

Adding abiraterone plus prednisone to ADT improves patient-reported outcomes and quality of life in patients with metastatic castration-naive prostate cancer.

Educational strategies including pamphlets and recommendations from family physicians and support from a specialist can improve bone care in men with prostate cancer undergoing androgen deprivation therapy.

The use of bipolar androgen therapy was safe and resulted in responses to enzalutamide in metastatic castration-resistant prostate cancer patients after initial therapy.

Multiple immunotherapy platforms have been investigated for prostate cancer, but sipuleucel-T still remains the sole approved autologous cellular immune product that can be used in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.

A novel classification system that incorporates genomic risk with clinical variables was able to accurately identify prostate cancer patients at low, intermediate, and high risk for metastasis.

In this review, we will examine the theories supporting treatment to achieve local disease control in oligometastatic prostate cancer, analyze the evidence supporting cytoreductive prostatectomy, and review selected relevant ongoing clinical trials.

Quality of life is better after modern radiotherapy compared with surgery.

Most men with clinically important localized prostate cancer deserve first-line open or robotic radical prostatectomy.

Men with Medicaid are more likely to present with metastatic prostate cancer than men presenting with prostate cancer who have private insurance, according to a new study. There are racial disparities in terms of prostate cancer outcomes among those privately insured, but not among Medicaid recipients.

In this interview we discuss the STOPCaP trial, a meta-analysis that looked at optimal systemic therapy options for men with metastatic hormone-sensitive prostate cancer.

Serial PSA testing with early salvage radiotherapy is a viable option in most high-risk men.

The data for adjuvant radiotherapy remain strong.

This video reviews 4-year quality-of-life results from a prospective, population-based study that looked at prostate cancer patients who selected either active surveillance, radical prostatectomy, or external-beam radiation.

This video highlights a new study that found that markers of immune response in prostate cancer may be able to predict patients’ response to radiation therapy, likelihood of recurrence, and survival.

This video highlights potentially practice-changing studies on genitourinary cancers presented at the 2017 ASTRO Annual Meeting.

The presence of more comorbidities had an effect on all-cause mortality, but not prostate cancer-specific mortality, in a large cohort study of men with prostate cancer.

The first head-to-head comparison of docetaxel and abiraterone acetate for high-risk prostate cancer patients starting long-term hormone therapy found benefit with both treatments when added to ADT. Treatment decisions may come down to specific toxicities, which differ between the treatments.

An analysis that corrected for differences in implementation found that the two main trials of prostate cancer screening in Europe and the United States both show a reduction in prostate cancer mortality with screening.